Articles tagged with Metastasis
Researchers identified an enzyme, p38α kinase, as crucial for metastasis, which is the primary cause of cancer deaths. By blocking this enzyme using an inhibitor, they successfully reduced melanoma's spread to the lungs and prolonged survival time.
A new method for predicting the evolution of melanoma uses the quantification of BRAF-V600E mutation load as a prognostic marker. The study found that patients with lower levels of this mutation in their primary tumours were more likely to develop metastasis, suggesting its potential use as a predictor of progress to metastasis.
A new study reveals that lymph node and distant metastases develop through different evolutionary mechanisms, with lymph nodes being a genetically highly diverse group. This suggests that metastasis formation in locoregional lymph nodes is comparatively easy and can be achieved by many cells, whereas dissemination to and outgrowth in d...
Researchers have found that genetic mutations from birth can promote cancer metastasis, with a single gene variant ApoE4 associated with slower tumor growth and better immune response. This discovery may lead to personalized treatment approaches for patients based on their genetics.
Mutations in TP53 and concomitant mutant p53 proteins in cancer cells have been found to accelerate tumorigenesis and metastasis. The researchers found that the combination of gain of function mutations and loss of heterozygosity provides protection against cell death, promoting a fibrotic microenvironment and inflammation pathways.
Researchers at City of Hope have identified a novel microRNA biomarker that can detect lymph node metastases in pancreatic ductal adenocarcinoma, which makes up about 80% of all pancreatic cancer cases. The test has an accuracy level of 78% and could lead to more personalized treatment strategies for patients.
Researchers at Université catholique de Louvain discovered that cancer cells can deactivate the CD166 'Velcro' protein on their surface, allowing them to migrate more easily and form metastases. This fundamental mechanism may lead to the development of new solutions to block metastasis and slow down cancer progression.
Researchers at DKFZ successfully blocked a receptor that stimulates tumor growth and metastasis with an antibody, slowing down cancer progression. The study found that the antibody reduced metastases in treated mice without affecting blood vessel formation.
A virtual computational cell was built to predict cancer metastasis by analyzing the interaction of numerous molecules and signals within the tumor environment. The research found that hybrid cancer cells can be targeted using specific molecular signals and extracellular matrix proteins, offering new therapeutic strategies against cancer.
A phase II clinical trial found that stereotactic ablative radiation (SABR) slowed disease progression in a subset of men with limited spread of prostate cancer. SABR treatment was associated with an expanded population of T cells, suggesting a full-body immune system response to their cancers.
A randomized trial of high-dose targeted radiation versus observation found no significant difference in progression prevention among 54 men with recurrent hormone-sensitive prostate cancer. The study suggests that observation may be a viable alternative to radiation therapy for this patient population.
Researchers found that osimertinib, commonly used to treat non-small cell lung cancer, showed benefits for patients with metastatic brain cancers, with 64% experiencing a measurable response and 90% disease control in the central nervous system.
Jason Gleghorn is developing microfluidic devices to culture entire lymph nodes outside the body, enabling real-time study of cell behavior. The project aims to understand chronic infection and inflammation, as well as drug delivery strategies for chemotherapy and antiretroviral therapies.
Researchers at UC Davis have discovered that changes in surface sugarlike molecules, or glycans, on cancer cells help them metastasize. The study found that cancer cells with high levels of mannose glycan were more likely to spread into surrounding tissues.
Researchers at NYU Abu Dhabi have developed a microfluidic platform that allows for the isolation and study of circulating tumor cells (CTCs) from blood samples. The platform enables high precision analysis of CTCs' mechanical properties at the single cell level, holding potential for early cancer detection and monitoring.
Researchers have developed a new contrast agent that detects brain metastases in certain types of cancer, such as breast cancer, at an early stage using minimal amounts of contrast agent. The agent works by detecting the formation of new blood vessels, improving MRI sensitivity and visualization.
A new study from Tulane University has identified a protein on tumor-derived extracellular vesicles that indicates if NSCLC tumors are likely to metastasize. This discovery could lead to the development of an early diagnostic test for patients at high risk of cancer spread.
Researchers have discovered that breast cancer cells change their metabolism to move to other parts of the body, a finding that could lead to new strategies for preventing the spread of cancer. This shift in metabolism may be targeted with drugs to prevent metastasis and improve survival rates.
A study of 30,180 patients with papillary thyroid microcarcinoma found that nearly 20% had pathological signs of aggressive disease, increasing the risk of distant metastasis. The research emphasizes the need for new preoperative tests to identify high-risk tumors and thorough patient counseling on all treatment options.
Cancer cells exploit a protein to break through tissue boundaries, increasing motility and invasiveness.
A new radiopharmaceutical, [55Co]Co-DOTATATE, has been developed to aid in the diagnosis of neuroendocrine tumor metastases. It resulted in superior image contrast and enhanced detection compared to commonly used imaging agents.
A pilot study by researchers at the University of Cincinnati shows that radiation therapy before immunotherapy may increase patient survival for those with brain metastases. The combination therapy was found to be superior to radiation alone, with genes associated with cell death signaling and inflammation present in tissue.
Research reveals some extra chromosomes in cancer cells can inhibit metastasis and even increase survival rates for patients. A study published in Developmental Cell found beneficial aneuploidies associated with increased survival, contrary to the long-held notion that aneuploidy always skews gene activity towards aggressive cancers.
Researchers found that WDR74 protein enhances the ability of circulating tumor cells to metastasize in both lung cancer and melanoma. The protein's presence increases oncogenic properties, while its absence decreases metastatic potential.
Researchers from Massachusetts General Hospital Cancer Center identified an adaptation by cancer cells that facilitates their spreading to distant sites. Targeted therapies disrupting the ribosome function and inhibiting cancer cell growth slows the spread of breast cancer in a mouse model.
Cancer cells can change their developmental identity, enabling them to spread and evade the immune system. Researchers identified specific cell types involved in lung development that are also present in cancer metastases.
A new biomarker for detecting liver metastases has been identified by a Georgia State University research team. The breakthrough uses a targeted MRI contrast agent that can pinpoint tiny instances of cancer cells, overcoming major barriers in early diagnosis.
A Cedars-Sinai team will investigate the interplay between dietary fat and fatty liver disease to understand how cancer spreads to the liver and find ways to block it. The study aims to identify key mechanisms that allow cancer to spread to the liver and develop potential treatments.
A new study suggests that targeting Hsp47 could block cancer cell-platelet interaction and inhibit metastasis in triple-negative breast cancer patients. The protein is often amplified in the genes of metastatic breast cancer tissue, potentially serving as a biomarker for metastasis.
A team at Tohoku University discovered that BACH1 facilitates pancreatic cancer spread by reducing cell-to-cell adhesion. Silencing or overexpressing BACH1 in pancreatic cancer cells reduced metastasis and improved survival rates.
Researchers found improved survival times of 13.6 months and 17.8 months for uveal melanoma patients with liver metastasis treated with new therapies, compared to 5.3 months in earlier years. The shift from systemic chemotherapy to targeted liver treatments has led to significant benefits.
A new study published in Nature Communications found that sevoflurane anesthesia leads to more metastatic burden in the lung after breast tumor resecting surgery than propofol. The findings may guide clinicians in optimizing anesthesia choice for breast cancer surgery to achieve best long-term outcomes.
A study found that increased LOXL2 protein levels in alveolar rhabdomyosarcoma cells promote metastasis. The protein's role in regulating metastatic function remains unclear, but it interacts with vimentin, a cytoskeletal protein involved in cell migration.
Chronic exposure to interleukin-1-beta promotes lung cancer metastasis by altering gene expression, enabling cancer cells to adopt a phenotype that facilitates distance organ colonization. The study provides new insights into the role of chronic inflammation in tumor progression and metastasis.
Researchers found that protein AKAP8 inhibits breast cancer metastasis by interfering with proteins that promote metastatic behavior. AKAP8 also predicts metastatic breast cancer outcomes in patients and can inhibit progression in animal models.
Isolated limb infusion (ILI) is a new method for treating melanoma metastases confined to an extremity, offering a more targeted and less exhausting alternative to systemic chemotherapy. The study found an overall response rate of 76% and long-term limb salvage rate of 90%, comparable to high-volume centers in the US and Australia.
Cancer cells store lipids in vesicles called lipid droplets, making them more invasive and prone to forming metastases. The researchers found that TGF-beta2 is the switch responsible for both lipid storage and aggressive cancer cell behavior.
Researchers developed a new compound that targets microRNA-21, a molecule linked to aggressive breast cancer, awakening its self-destruct system and killing cancer cells while leaving healthy cells unaffected. In mouse models, the compound showed promise in reducing breast cancer spread and decreasing invasiveness in other cancers.
Researchers found that estrogen regulates accumulation of immune cells in the liver, promoting tumor growth and immune suppression. The study suggests exploring sex hormones in female cancer patients and using anti-estrogen drugs to improve immunotherapy outcomes.
Researchers discovered that restoring BMP4 activity blocks distant metastasis in multiple organs, including the lung and bone. High levels of BMP4 are associated with better patient outcomes.
Researchers have found that MYC and TWIST1, two genes that promote cancer development, work together to recruit immune cells to tumors, creating an environment that facilitates cancer cell spread. Blocking a key step in this process may help prevent metastasis.
Scientists identified a new biological pathway (RICTOR/mTORC2) as a potential therapeutic target for colon cancer. Targeting this pathway could enhance the effectiveness of chemotherapy treatments. The study also highlights the importance of SMAD4 gene mutations in colon cancer progression.
Fibroblasts play a crucial role in wound healing but also facilitate tumor growth and metastases in breast cancer. Inhibiting inflammatory signaling pathways may prevent metastatic relapse, say researchers from Tel Aviv University.
Researchers at UT Southwestern Medical Center have uncovered why certain melanoma cells are more likely to spread through the body. Efficient metastasizers take up more lactate due to higher levels of monocarboxylate transporter 1, allowing them to survive in the blood and promoting disease progression.
The pooled analysis of three clinical trials shows entrectinib is effective in 77% of patients with ROS1+ NSCLC and 57% of patients with NTRK+ NSCLC, with significant response rates and progression-free survival times. Entrectinib's ability to penetrate brain metastases makes it a promising treatment for these patients.
Researchers developed DeepMACT, a novel algorithm that can detect and analyze cancer metastases more than 300 times faster than human experts. The algorithm provides insights into the unique metastatic profiles of different tumor models, enabling tailored drug targeting for various cancers.
The trial showed that adding tucatinib to capecitabine and trastuzumab improved progression-free and overall survival in advanced HER2-positive breast cancer patients, regardless of whether they had brain metastasis. The treatment combination also increased the overall response rate compared to standard care.
A new study published in British Journal of Cancer has identified the protein stathmin as a crucial player in the spread of neuroblastoma. Stathmin helps regulate PTPN14 expression, affecting migration and invasion of neuroblastoma cells.
UConn researchers have discovered a connection between pregnancy and cancer metastasis in various mammal species. They found that certain species have evolved to make their stromal cells highly resistant to invasion, unlike humans who are more vulnerable to cancer metastasis.
Researchers established B6CaP, a prostate-derived tumor line that frequently metastasizes to bones and grows in an immunocompetent host, overcoming limitations of previous models. This model is useful for studying mechanisms of bone metastasis and tumor immune response.
A University of Colorado Cancer Center study suggests two new approaches to treating bone metastases from prostate cancer: targeting different signaling pathways for lytic and blastic lesions. Both types of bone metastases show promise with anti-cancer immunotherapy, particularly those with high PD-L1 levels.
A study discovered contagious cancer in shellfish that has spread across the Atlantic Ocean and into the Pacific. Researchers believe ships may have transported infected mussels, delivering the disease to new regions. The findings could help develop plans to protect marine life and inform human cancer metastasis research.
A new mathematical model predicts the presence of undetectable metastases based on primary tumor size, which is associated with a poorer prognosis. The model accurately reflects clinical study data for several cancer types, highlighting the potential dangers of delays in surgery for smaller tumors.
The study found that T-DM1 resulted in a third of patients experiencing objective response and nearly 40% continuing treatment for at least six months. Patients with central nervous system metastases had shorter progression-free survival rates, highlighting the need for inclusion in randomized trials.
Researchers found that prostate cancer bone metastases produce high levels of TGF-β, which crowds out helpful T cells needed for effective treatment. Combining anti-TGF-β with checkpoint inhibitors may reverse resistance and improve outcomes.
Purdue University scientists have identified key changes in the blood-brain barrier that hinder effective drug delivery to brain tumors. The discovery aims to improve treatment plans and patient outcomes for those with brain metastases from breast, lung, and melanoma.
The study found that tumor cells undergoing epithelial to mesenchymal transition (EMT) play a key role in metastasis. However, the reverse transition, MET, is occurring at the metastatic site, suggesting that EMT is not always required for metastasis.
Researchers have identified CEMIP as a key protein promoting brain metastasis in breast and lung cancers. By blocking CEMIP, it may be possible to prevent or treat brain metastases, which are a common cause of cancer deaths. High levels of CEMIP in primary tumors have been linked to a faster progression to brain metastasis.
Researchers analyzed BTB and BBB changes in NSCLC brain metastasis over time, revealing key changes including loss of aquaporin-4 and zona occludens-1. These findings provide a comprehensive analysis of the transition of the blood-brain barrier to the blood-tumor barrier.
A study has developed a method to determine activity in bone marrow, enabling personalized dosimetry. This approach can predict the effectiveness of treatment and prevent bone marrow toxicity.